Compare Abeona Therapeutics Inc (ABEO) vs Clorox Co (CLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Clorox Co — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Clorox Co trades at $94.77 (market cap $11.78B). The key difference: Clorox Co is far larger — about 31.6× Abeona Therapeutics Inc's market cap, and Clorox Co pays a 5.09% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CLX | |
|---|---|---|
Market Cap | $373.32M | $11.78B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $131.43 |
52-Week Low | $4.17 | $86.12 |
Enterprise Value | $228.22M | $15.08B |
Dividend Yield | — | 5.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CLX trades at $97.41, up 0.15% on the day, with a neutral technical signal and key support at $96. The company reported Q1 2026 EPS of $1.64, beating expectations, and maintains strong profitability with an 11.18% net margin. Recent news highlights a simplified operating structure and CEO transition, while analyst consensus is a $103.38 price target with a hold-heavy rating distribution.
The outlook is mixed: solid fundamentals and a nearly 5% dividend yield support income investors, but high debt levels and competitive pressures pose risks. Upside depends on execution of new growth initiatives under incoming leadership, with current valuation appearing reasonable relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
